The risks of HBV infection after liver transplantation from HBc antibody positive donor to HBs antibody positive recipient

Toru Ikegami, Akinobu Taketomi, Ryuji Ohta, Yiji Soejima, Tomoharu Yoshizumi, Noboru Harada, Mitsuo Shimada, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

The rate of de novo hepatitis B infection, after liver transplantation from a hepatitis B core antibody (HBcAb) (+) donor to a surface antibody (HBsAb) (+) recipient bas not yet elucidated. Four recipients with HBsAb (+) and HBcAb, (+), who received living donor grafts from HBcAb (+) donors were herein reviewed. They received lamivudine monotherapy: three patients with HBsAb titer >10 IU/L did not demonstrate the onset of HBsAg, whereas one patient with HBsAb titer <10 IU/L developed hepatitis B antigen (HBsAg) 4 years after transplantation. An HBsAb (+) patient with a titer of >10 IU/L is therefore considered not to require combination therapy when receiving an HBcAb (+) liver graft. However, a great deal of caution is necessary in patients with a negative or low HBsAb titers <10 IU/L.

Original languageEnglish
Pages (from-to)2162-2165
Number of pages4
JournalHepato-gastroenterology
Volume55
Issue number88
Publication statusPublished - Nov 2008

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'The risks of HBV infection after liver transplantation from HBc antibody positive donor to HBs antibody positive recipient'. Together they form a unique fingerprint.

Cite this